Last updated on February 2019

Study of the Efficacy Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis


Brief description of study

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Clinical Study Identifier: NCT03546816

Contact Investigators or Research Sites near you

Start Over

Principal Investigator

Study Site 221
Bryant, AR United States
  Connect »

Principal Investigator

Study Site 204
Fremont, CA United States
  Connect »

Principal Investigator

Study Site 383
North Hollywood, CA United States
  Connect »

Principal Investigator

Study Site 356
San Diego, CA United States
  Connect »

Principal Investigator

Study Site 514
Santa Ana, CA United States
  Connect »

Principal Investigator

Study Site 501
Aventura, FL United States
  Connect »

Principal Investigator

Study Site 222
North Miami Beach, FL United States
  Connect »

Principal Investigator

Study Site 519
Orange Park, FL United States
  Connect »

Principal Investigator

Study Site 510
Newnan, GA United States
  Connect »

Principal Investigator

Study Site 506
Ann Arbor, MI United States
  Connect »

Principal Investigator

Study Site 209
Fridley, MN United States
  Connect »

Principal Investigator

Study Site 371
Saint Joseph, MO United States
  Connect »

Principal Investigator

Study Site 227
Omaha, NE United States
  Connect »

Principal Investigator

Study Site 201
East Windsor, NJ United States
  Connect »

Principal Investigator

Study Site 508
Buffalo, NY United States
  Connect »

Principal Investigator

Study Site 517
New York, NY United States
  Connect »

Principal Investigator

Study Site 112
Tulsa, OK United States
  Connect »

Principal Investigator

Study Site 345
Johnston, RI United States
  Connect »

Principal Investigator

Study Site 511
Knoxville, TN United States
  Connect »

Principal Investigator

Study Site 224
Houston, TX United States
  Connect »

Principal Investigator

Study Site 359
Pflugerville, TX United States
  Connect »

Principal Investigator

Study Site 361
San Antonio, TX United States
  Connect »

Principal Investigator

Study Site 226
Webster, TX United States
  Connect »

Principal Investigator

Study Site 515
Detroit, MI United States
  Connect »

Principal Investigator

Study Site 503
New York, NY United States
  Connect »

Principal Investigator

Study Site 341
High Point, NC United States
  Connect »

Principal Investigator

Study Site 516
Bexley, OH United States
  Connect »

Principal Investigator

Study Site 502
Dallas, TX United States
  Connect »

Principal Investigator

Study Site 210
Coral Gables, FL United States
  Connect »

Principal Investigator

Study Site 228
Louisville, KY United States
  Connect »

Principal Investigator

Study Site 500
New York, NY United States
  Connect »

Principal Investigator

Study Site 509
Cleveland, OH United States
  Connect »

Principal Investigator

Study Site 524
Dublin, OH United States
  Connect »

Principal Investigator

Study Site 365
Austin, TX United States
  Connect »

Principal Investigator

Study Site 520
Bellaire, TX United States
  Connect »

Principal Investigator

Study Site 525
Glenn Dale, MD United States
  Connect »

Principal Investigator

Study Site 526
Henderson, NV United States
  Connect »

Principal Investigator

Study Site 507
Brooklyn, NY United States
  Connect »

Principal Investigator

Study Site 522
Pittsburgh, PA United States
  Connect »

Principal Investigator

Study Site 527
New Orleans, LA United States
  Connect »

Principal Investigator

Study Site 379
Boston, MA United States
  Connect »

Principal Investigator

Study Site 523
Philadelphia, PA United States
  Connect »

Principal Investigator

Study Site 504
Birmingham, AL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.